Compare ASPN & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASPN | VNDA |
|---|---|---|
| Founded | 2001 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | RETAIL: Building Materials | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 573.2M | 474.0M |
| IPO Year | 2011 | 2005 |
| Metric | ASPN | VNDA |
|---|---|---|
| Price | $3.23 | $7.84 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $4.25 | ★ $14.90 |
| AVG Volume (30 Days) | 1.7M | ★ 3.6M |
| Earning Date | 05-25-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 125.76 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $452,699,000.00 | $216,105,000.00 |
| Revenue This Year | N/A | $21.50 |
| Revenue Next Year | $38.29 | $38.67 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 89.64 | 8.72 |
| 52 Week Low | $2.30 | $3.81 |
| 52 Week High | $9.78 | $9.60 |
| Indicator | ASPN | VNDA |
|---|---|---|
| Relative Strength Index (RSI) | 46.75 | 52.82 |
| Support Level | $2.89 | $4.25 |
| Resistance Level | $3.80 | $8.29 |
| Average True Range (ATR) | 0.27 | 0.53 |
| MACD | -0.01 | 0.07 |
| Stochastic Oscillator | 64.46 | 63.39 |
Aspen Aerogels Inc is an aerogel technology company that designs, develops, and manufactures high-performance aerogel insulation used in the energy industrial and sustainable insulation markets. The company also conducts research and development related to aerogel technology supported by funding from several agencies of the United States of America government and other institutions in the form of research and development contracts. It is engaged in two operating segment Energy Industrial and Thermal Barrier. Geographically, it operates in the U.S. and also has a presence in other International countries. It generates the majority of its revenue from the Energy Industrial segment and the United States market. Some of its products include Pyrogel XTE; Cryogel Z; Spaceloft Subsea; and others.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.